Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2005 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00155376
First received: September 8, 2005
Last updated: November 25, 2005
Last verified: April 2005
  Purpose

Morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile secretion and dilatation of bile duct. We conduct this randomized double blinded study to evaluate the effect of enhancement in MRCP using intravenous morphine and glucagon.


Condition Intervention Phase
Liver Disease
Drug: morphine and glucagon
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Diagnostic

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • MRCP visibility

Estimated Enrollment: 100
Study Start Date: September 2005
Estimated Study Completion Date: September 2005
Detailed Description:

Morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile secretion and dilatation of bile duct. We conduct this randomized double blinded study to evaluate the effect of enhancement in MRCP using intravenous morphine and glucagon.

  Eligibility

Ages Eligible for Study:   20 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • normal volunteer
  • living liver donor

Exclusion Criteria:

  • COPD
  • chronic liver disease
  • hypersensitive to glucagon
  • DM
  • insulinoma
  • glucagonoma
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00155376

Contacts
Contact: Yuan-Heng Mo, MD jamesmyh@ha.mc.ntu.edu.tw

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, province of Taiwan, Taiwan, 100
Contact: Yuan-Heng Mo, MD       jamesmyh@ha.mc.ntu.edu.tw   
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Study Chair: Hon-Man Liu, MD National Taiwan University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00155376     History of Changes
Other Study ID Numbers: 940104
Study First Received: September 8, 2005
Last Updated: November 25, 2005
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Liver Diseases
Digestive System Diseases
Glucagon
Glucagon-Like Peptide 1
Morphine
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Gastrointestinal Agents
Therapeutic Uses
Incretins
Analgesics, Opioid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Central Nervous System Depressants
Narcotics

ClinicalTrials.gov processed this record on July 22, 2014